IP Library Granted Patent US 6,921,542
Granted Patent B2
US 6,921,542 · App. 10/201,210 · Granted Jul 26, 2005

Preparation of a therapeutic composition

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 6,921,542
App. No.
10/201,210
Granted
Jul 26, 2005
Kind
B2
Abstract

Product R, a novel therapeutic composition for treating viral infections and stimulating the immune system, comprises a unique peptide having 31 amino acids and another unique peptide having 21 amino acids and connected with an oligo-nucleotide through a diphosphodiester or diphosphodithioate ester linkage. The composition has a light absorption spectrum with typical absorption ratios of 1.998 at 260 nm/280 nm and 1.359 at 260 nm/230 nm.

Claims (5)

1. A pharmaceutical composition, comprising (a) a peptide nucleic acid preparation that absorbs light at wavelengths 230 nm, 260 nm and 280 nm so as to result in 260 nm/280 nm absorption ratio of about 1.998 and 260 nm/230 nm absorption ratio of about 1.359, comprising molecules of nucleotides resulting from a plant RNA and peptides resulting from a mixture of casein, beef peptone and bovine serum albumin, said molecules having non-uniformly distributed molecular weights, and (b) a pharmaceutically acceptable carrier.

2. The composition of claim 1 , wherein said nucleotides comprise mono-nucleotides.

3. The composition of claim 1 , wherein said molecules have non-uniformly distributed molecular weights in a range from zero to substantially not more than 14 KDa by silver staining.

4. The composition of claim 1 , wherein said molecules have non-uniformly distributed molecular weights in a range from zero to substantially not more than 8 KDa by silver staining.

5. The composition of claim 1 , wherein said molecules have substantial concentrations at molecular weights of substantially 5.2 KDa and 4.3 KDa by silver staining.

Assignments (6)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 25, 2013
From: FRIEDLAND, BERNARD; HIRSCHMAN, SHALOM Z.; TARAPOREWALA, IRACH B.
To: ADVANCED VIRAL RESEARCH CORP.
Reel/Frame 029692/0663 →
MERGER Recorded Jan 25, 2013
From: BBM HOLDINGS, INC.
To: OHR PHARMACEUTICAL, INC.
Reel/Frame 029692/0782 →
SECURITY AGREEMENT Recorded May 20, 2009
From: BBM HOLDINGS, INC.
To: YA GLOBAL INVESTMENTS, L.P.
Reel/Frame 022708/0679 →
CORRECTIVE ASSIGNMENT TO CORRECT THE RECEIVING PARTY PREVIOUSLY RECORDED ON REEL 022542 FRAME 0001. ASSIGNOR(S) HEREBY CONFIRMS THE OWNERSHIP TRANSFERED FROM ADVANCED VIRAL RESEARCH CORP. AND TRIAD BIOTHERAPEUTICS, INC. TO BBM HOLDINGS, INC. Recorded Apr 30, 2009
From: ADVANCED VIRAL RESEARCH CORP.; TRIAD BIOTHERAPEUTICS, INC.
To: BBM HOLDINGS, INC.
Reel/Frame 022629/0569 →
CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNOR/ASSIGNEE NAMES PREVIOUSLY RECORDED ON REEL 022510 FRAME 0187. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNORS ARE ADVANCED VIRAL RESEARCH CORP. AND TRIAD BIOTHERAPEUTICS, INC., AND THE ASSIGNEE IS YA GLOBAL INVESTMENTS, L.P. Recorded Apr 14, 2009
From: ADVANCED VIRAL RESEARCH CORP.; TRIAD BIOTHERAPEUTICS, INC.
To: YA GLOBAL INVESTMENTS, L.P. (F/K/A CORNELL CAPITAL PARTNERS, L.P.)
Reel/Frame 022542/0001 →
FORECLOSURE BY THIRD PARTY Recorded Apr 6, 2009
From: YA GLOBAL INVESTMENTS, L.P. (F/K/A CORNELL CAPITAL PARTNERS, L.P.)
To: ADVANCED VIRAL RESEARCH CORP.; TRIAD BIOTHERAPEUTICS, INC.
Reel/Frame 022510/0187 →